Why are investors glomming onto a multiple sclerosis drug with very iffy data?
View More: http://feeds.thestreet.com/~r/tsc/feeds/rss/latest-stories/~3/zDKKJGUssE0/opexas-surge-a-headscratcher-biobuzz.html
You must be logged in to post a comment.
By confirming my cell number, I agree that I am responsible for all of my carrier text messaging charges.